PET neuroimaging of [11C]mirtazapine enantiomers in pigs

European Neuropsychopharmacology

Volumn 16, Issue 5, 2006, Pages 350-357

  Smith, Donald F ^a   Marthi, Katalin ^b   Munk, Ole L ^c   Cumming, Paul ^c   Hansen, Søren B ^c   Jakobsen, Steen ^c  

^a AARHUS UNIVERSITY   (Denmark)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

11C Mirtazapine; Antidepressant; Enantiomers; PET neuroimaging; Pharmacokinetics; Porcine brain

Indexed keywords

MIRTAZAPINE; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; MIANSERIN; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DOSIMETRY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; ENANTIOMER; ENANTIOSELECTIVITY; FEMALE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DETECTION; RADIATION DOSE DISTRIBUTION; TISSUE DISTRIBUTION; ANIMAL; BLOOD; BLOOD ANALYSIS; BRAIN; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; RADIOMETRY; SCINTISCANNING; STEREOISOMERISM; SWINE; WHOLE BODY COUNTING;

ANIMALS; BLOOD CHEMICAL ANALYSIS; BRAIN; CARBON RADIOISOTOPES; FEMALE; INJECTIONS, INTRAVENOUS; ISOTOPE LABELING; MIANSERIN; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; STEREOISOMERISM; SWINE; WHOLE-BODY COUNTING;

EID: 33744535679     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2005.10.008     Document Type: Article

References (42)

1. Adams K.H., Pinborg L.H., Svarer C., Hasselbalch S.G., Holm S., Haugbol S., Madsen K., Frokjaer V., Martiny L., Paulson O.B., and Knudsen G.M. A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage 21 (2004) 1105-1113
2. Ariens E.J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 26 (1984) 663-668
3. Baker G.B., and Prior T.I. Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs. Ann. Med. 34 (2002) 537-543
4. Barraud d.L., Comets E., Gautrand C., Fernandez C., Auchere D., Singlas E., Mentre F., and Gimenez F. Cerebral uptake of mefloquine enantiomers with and without the P-gp inhibitor elacridar (GF1210918) in mice. Br. J. Pharmacol. 141 (2004) 1214-1222
5. Baumann P., Zullino D., and Eap C. Enantiomers' potential in psychopharmacology-a critical analysis with special emphasis on the antidepressant escitalopram. Eur. Neuropsychopharmacol. 12 (2002) 433
6. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur. Neuropsychopharmacol. 13 (2003) 57-66
7. Cidis M.C., Drevets W.C., Price J.C., Mathis C.A., Lopresti B., Greer P.J., Villemagne V.L., Holt D., Mason N.S., Houck P.R., Reynolds III C.F., and DeKosky S.T. Gender-specific aging effects on the serotonin 1A receptor. Brain Res. 895 (2001) 9-17
8. Cristy, M. and Eckerman, K. Specific absorbed fractions of energy at various ages from internal photon sources. I-VII. ORNL/TM-8381 V1-V7. 1987. Oak Ridge National Laboratory. Ref Type: Pamphlet.
9. de Boer T. The pharmacologic profile of mirtazapine. J Clin. Psychiatry 57 Suppl 4 (1996) 19-25
10. de Boer T.H., Maura G., Raiteri M., de Vos C.J., Wieringa J., and Pinder R.M. Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology 27 (1988) 399-408
11. De Vos H., Convents A., De Keyser J., De Backer J.P., Van Megen I.J., Ebinger G., and Vauquelin G. Autoradiographic distribution of alpha 2 adrenoceptors, NAIBS, and 5-HT1A receptors in human brain using [3H]idazoxan and [3H]rauwolscine. Brain Res. 566 (1991) 13-20
12. De Vos H., Bricca G., De Keyser J., De Backer J.P., Bousquet P., and Vauquelin G. Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system. Neuroscience 59 (1994) 589-598
13. Gillings N.M., Bender D., Falborg L., Marthi K., Munk O.L., and Cumming P. Kinetics of the metabolism of four PET radioligands in living minipigs. Nucl. Med. Biol. 28 (2001) 97-104
14. Grasmader K., Verwohlt P.L., Kuhn K.U., Dragicevic A., von Widdern O., Zobel A., Hiemke C., Rietschel M., Maier W., Jaehde U., and Rao M.L. Population pharmacokinetic analysis of mirtazapine. Eur. J Clin. Pharmacol. 60 (2004) 473-480
15. International Commission on Radiological Protection. ICRP Publication 80. Radiation dose to patients from radiopharmaceuticals (Addendum 2 to ICRP Publication 53). 1997. Annals of the ICRP, Pergamon. Ref Type: Pamphlet.
16. Kent J.M. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 355 (2003) 911-918
17. Kooyman A.R., Zwart R., Vanderheijden P.M., Van Hooft J.A., and Vijverberg H.P. Interaction between enantiomers of mianserin and ORG3770 at 5-HT3 receptors in cultured mouse neuroblastoma cells. Neuropharmacology 33 (1994) 501-507
18. 11C]raclopride studies. J. Cereb. Blood Flow Metab. 16 (1996) 42-52
19. Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb. Blood Flow Metab. 20 (2000) 423-451
20. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J., et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 10 (1990) 740-747
21. 11C]Mirtazapine for PET neuroimaging: radiosynthesis and initial evaluation in the living porcine brain. Eur. Neuropsychopharmacol. 12 (2002) 427-432
22. Marthi K., Hansen S.B., Jakobsen S., Bender D., Smith S.B., and Smith D.F. Biodistribution and radiation dosimetry of [N-methyl-11C]mirtazapine, an antidepressant affecting adrenoceptors. Appl. Radiat. Isotopes 59 (2003) 175-179
23. Marthi K., Jakobsen S., Bender D., Hansen S.B., Smith S.B., Hermansen F., Rosenberg R., and Smith D.F. [N-methyl-11C]Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. Psychopharmacology (Berl) 174 (2004) 260-265
24. Mejia A.A., Nakamura T., Masatoshi I., Hatazawa J., Masaki M., and Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J. Nucl. Med. 32 (1991) 699-706
25. Nickolson V.J., Wieringa J.H., and Van D.A. Comparative pharmacology of mianserin, its main metabolites and 6-azamianserin. Naunyn-Schmiedeberg's Arch. Pharmacol. 319 (1982) 48-55
26. O'Connor W.T., and Leonard B.E. Effect of chronic administration of the 6-aza analogue of mianserin (ORG. 3770) and its enantiomers on behavior and changes in noradrenaline metabolism of olfactory-bulbectomized rats in the "open field" apparatus. Neuropharmacology 25 (1986) 267-270
27. Paus E., Jonzier-Perey M., Cochard N., Eap C.B., and Baumann P. Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS. Ther. Drug Monit. 26 (2004) 366-374
28. Pike V.W., McCarron J.A., Lammertsma A.A., Osman S., Hume S.P., Sargent P.A., Bench C.J., Cliffe I.A., Fletcher A., and Grasby P.M. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. Eur. J. Pharmacol. 301 (1996) R5-R7
29. Poulsen P.H., Smith D.F., Ostergaard L., Danielsen E.H., Gee A., Hansen S.B., Astrup J., and Gjedde A. In vivo estimation of cerebral blood flow, oxygen consumption and glucose metabolism in the pig by [15O]water injection, [15O]oxygen inhalation and dual injections of [18F]fluorodeoxyglucose. J. Neurosci. Methods 77 (1997) 199-209
30. Ramos C.D., Erdi Y.E., Gonen M., Riedel E., Yeung H.W., Macapinlac H.A., Chisin R., and Larson S.M. FDG-PET standardized uptake values in normal anatomical structures using iterative reconstruction segmented attenuation correction and filtered back-projection. Eur. J. Nucl. Med. 28 (2001) 155-164
31. Sedvall G., Farde L., Persson A., and Wiesel F.A. Imaging of neurotransmitter receptors in the living human brain. Arch. Gen. Psychiatry 43 (1986) 995-1005
32. Smith D.F. The stereoselectivity of drug action. Pharmacol. Toxicol. 65 (1989) 321-331
33. 11C]venlafaxine: serotonin uptake inhibition, biodistribution and binding in living pig brain. Eur. Neuropsychopharmacol. 7 (1997) 195-200
34. Stabin M.G. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J. Nucl. Med. 37 (1996) 538-546
35. Szegedi A., and Schwertfeger N. Mirtazapine: a review of its clinical efficacy and tolerability. Expert. Opin. Pharmacother. 6 (2005) 631-641
36. Tang G., Wang M., Tang X., Luo L., and Gan M. Pharmacokinetics and radiation dosimetry estimation of O-(2-[18F]fluoroethyl)-l-tyrosine as oncologic PET tracer. Appl. Radiat. Isotopes 58 (2003) 219-225
37. Timmer C.J., Sitsen J.M., and Delbressine L.P. Clinical pharmacokinetics of mirtazapine. Clin. Pharmacokinet. 38 (2000) 461-474
38. Tomori H., Yoshihara H., and Ogura K. Facile optical resolution of a dibenzopyrazinoazepine derivative and the nature of molecular recognition of amines by chiral 2,3-di-O-/arylcarbonyl)tartaric acids. Bull. Chem. Soc. Jpn. 69 (1996) 3581-3590
39. Turkheimer F.E., Hinz R., and Cunningham V.J. On the undecidability among kinetic models: from model selection to model averaging. J. Cereb. Blood Flow Metab. 23 (2003) 490-498
40. Waldeck B. Three-dimensional pharmacology, a subject ranging from ignorance to overstatements. Pharmacol. Toxicol. 93 (2003) 203-210
41. Watanabe H., Andersen F., Simonsen C.Z., Evans S.M., Gjedde A., and Cumming P. MR-based statistical atlas of the gottingen minipig brain. NeuroImage 14 (2001) 1089-1096
42. 11C]pyrilamine and positron emission tomography. J. Neurochem. 59 (1992) 128-136